NCT04041037View on ClinicalTrials.gov

The Management of Pilonidal Wounds With ACell MicroMatrix® and Cytal® Wound Matrix: A Case Series

TerminatedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

November 5, 2019

Conditions
Pilonidal Disease
Interventions
DEVICE

Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix

Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.

Trial Locations (1)

33613

AdventHealth Tampa, Tampa

Sponsors
All Listed Sponsors
lead

Integra LifeSciences Corporation

INDUSTRY

NCT04041037 - The Management of Pilonidal Wounds With ACell MicroMatrix® and Cytal® Wound Matrix: A Case Series | Biotech Hunter | Biotech Hunter